Cargando…

Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions

The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis. In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive inflammatory response in patients, causing an inflammatory cytokine storm in severe cases. Cytokine storm leads to acute respiratory distress...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yujie, Zhao, Tingmei, Zhou, Xueyan, Xiang, Yu, Gutierrez‐Castrellon, Pedro, Ma, Xuelei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340488/
https://www.ncbi.nlm.nih.gov/pubmed/35923762
http://dx.doi.org/10.1002/mco2.154
_version_ 1784760416167002112
author Jiang, Yujie
Zhao, Tingmei
Zhou, Xueyan
Xiang, Yu
Gutierrez‐Castrellon, Pedro
Ma, Xuelei
author_facet Jiang, Yujie
Zhao, Tingmei
Zhou, Xueyan
Xiang, Yu
Gutierrez‐Castrellon, Pedro
Ma, Xuelei
author_sort Jiang, Yujie
collection PubMed
description The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis. In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive inflammatory response in patients, causing an inflammatory cytokine storm in severe cases. Cytokine storm leads to acute respiratory distress syndrome, pulmonary and other multiorgan failure, which is an important cause of COVID‐19 progression and even death. Among them, activation of inflammatory pathways is a major factor in generating cytokine storms and causing dysregulated immune responses, which is closely related to the severity of viral infection. Therefore, elucidation of the inflammatory signaling pathway of SARS‐CoV‐2 is important in providing otential therapeutic targets and treatment strategies against COVID‐19. Here, we discuss the major inflammatory pathways in the pathogenesis of COVID‐19, including induction, function, and downstream signaling, as well as existing and potential interventions targeting these cytokines or related signaling pathways. We believe that a comprehensive understanding of the regulatory pathways of COVID‐19 immune dysregulation and inflammation will help develop better clinical therapy strategies to effectively control inflammatory diseases, such as COVID‐19.
format Online
Article
Text
id pubmed-9340488
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93404882022-08-02 Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions Jiang, Yujie Zhao, Tingmei Zhou, Xueyan Xiang, Yu Gutierrez‐Castrellon, Pedro Ma, Xuelei MedComm (2020) Reviews The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis. In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive inflammatory response in patients, causing an inflammatory cytokine storm in severe cases. Cytokine storm leads to acute respiratory distress syndrome, pulmonary and other multiorgan failure, which is an important cause of COVID‐19 progression and even death. Among them, activation of inflammatory pathways is a major factor in generating cytokine storms and causing dysregulated immune responses, which is closely related to the severity of viral infection. Therefore, elucidation of the inflammatory signaling pathway of SARS‐CoV‐2 is important in providing otential therapeutic targets and treatment strategies against COVID‐19. Here, we discuss the major inflammatory pathways in the pathogenesis of COVID‐19, including induction, function, and downstream signaling, as well as existing and potential interventions targeting these cytokines or related signaling pathways. We believe that a comprehensive understanding of the regulatory pathways of COVID‐19 immune dysregulation and inflammation will help develop better clinical therapy strategies to effectively control inflammatory diseases, such as COVID‐19. John Wiley and Sons Inc. 2022-08-01 /pmc/articles/PMC9340488/ /pubmed/35923762 http://dx.doi.org/10.1002/mco2.154 Text en © 2022 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Jiang, Yujie
Zhao, Tingmei
Zhou, Xueyan
Xiang, Yu
Gutierrez‐Castrellon, Pedro
Ma, Xuelei
Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
title Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
title_full Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
title_fullStr Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
title_full_unstemmed Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
title_short Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
title_sort inflammatory pathways in covid‐19: mechanism and therapeutic interventions
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340488/
https://www.ncbi.nlm.nih.gov/pubmed/35923762
http://dx.doi.org/10.1002/mco2.154
work_keys_str_mv AT jiangyujie inflammatorypathwaysincovid19mechanismandtherapeuticinterventions
AT zhaotingmei inflammatorypathwaysincovid19mechanismandtherapeuticinterventions
AT zhouxueyan inflammatorypathwaysincovid19mechanismandtherapeuticinterventions
AT xiangyu inflammatorypathwaysincovid19mechanismandtherapeuticinterventions
AT gutierrezcastrellonpedro inflammatorypathwaysincovid19mechanismandtherapeuticinterventions
AT maxuelei inflammatorypathwaysincovid19mechanismandtherapeuticinterventions